# A Study of Rodatristat Ethyl in Patients With Pulmonary Arterial Hypertension (Core OLE)

> **NCT04712669** · PHASE2 · COMPLETED · sponsor: **Altavant Sciences GmbH** · enrollment: 108 (actual)

## Conditions studied

- Pulmonary Arterial Hypertension

## Interventions

- **DRUG:** rodatristat ethyl 300 mg tablet BID
- **DRUG:** rodatristat ethyl 600 mg BID
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04712669
- **Lead sponsor:** Altavant Sciences GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-03-15
- **Primary completion:** 2023-06-05
- **Final completion:** 2023-08-28
- **Target enrollment:** 108 (ACTUAL)
- **Last updated:** 2025-06-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04712669

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04712669, "A Study of Rodatristat Ethyl in Patients With Pulmonary Arterial Hypertension (Core OLE)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04712669. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*